National Pharmaceutical Pricing Authority (NPPA) has invoked the public interest clause in the Drugs Price Control Order to fix the price of an epileptic drug of Abbott Healthcare, the wholly owned subsidiary of the US pharmaceutical giant which sells the branded generic drugs it acquired from Piramal Healthcare in India. The country’s drug price regulator has fixed the price of Abbott’s Gardenal Syrup 60 ml at Rs 39.60 and given the company 15 days time to revise its price tag.he decision was taken after NPPA found the company had increased the price of this medicine by over 10 per cent between August 2007 and August 2008. The regulations allow drug companies to increase the prices of medicines (that are normally out of price control) up to 10 per cent during a 12-month period. NPPA monitors the prices of decontrolled (non-scheduled) medicines on the basis of data on price available from market research firm ORG IMS. The Authority also revised the prices of five bulk drugs — salbutamol sulphate, spironolactone, pheniramine maleate, chlopropamide and pyrantel pamoate — and announced a corresponding price revision of the medicine packs that use at least one of these bulk drugs as its ingredient. On the whole, NPPA has fixed the prices of 258 medicine packs on March 14. The authority has also fixed the price fixation parameters for non-PVC bags with oxygen barrier properties. The conversion cost, packing charges, packing material cost and process loss that will be calculated for fixing the prices of such bags will now be known to the industry.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac... -
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma... -
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th... -
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y... -
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after... -
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ... -
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment